tiprankstipranks
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS

Ionis Pharmaceuticals (IONS) Stock Forecast & Price Target

1,224 Followers
See the Price Targets and Ratings of:

IONS Analyst Ratings

Moderate Buy
16Ratings
10 Buy
5 Hold
1 Sell
Based on 16 analysts giving stock ratings to
Ionis
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

IONS Stock 12 Month Forecast

Average Price Target

$58.50
▲(38.49% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for Ionis Pharmaceuticals in the last 3 months. The average price target is $58.50 with a high forecast of $72.00 and a low forecast of $37.00. The average price target represents a 38.49% change from the last price of $42.24.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"plus_tr_sans","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"$35","54":"$54","73":"$73","44.5":"$44.5","63.5":"$63.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n  <span style=\"color:#199ca5\">$72.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":58.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n  <span style=\"color:#828080\">$58.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":37,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n  <span style=\"color:#912767\">$37.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,44.5,54,63.5,73],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2023","6":"Oct<br/>2023","9":"Jan<br/>2024","12":"Apr<br/>2024","25":"Apr<br/>2025"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.22,45.433846153846154,47.64769230769231,49.86153846153846,52.075384615384614,54.28923076923077,56.50307692307692,58.716923076923074,60.93076923076923,63.144615384615385,65.35846153846154,67.57230769230769,69.78615384615384,{"y":72,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.22,44.395384615384614,45.57076923076923,46.746153846153845,47.92153846153846,49.096923076923076,50.27230769230769,51.44769230769231,52.62307692307692,53.79846153846154,54.973846153846154,56.14923076923077,57.324615384615385,{"y":58.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,43.22,42.74153846153846,42.26307692307692,41.784615384615385,41.30615384615385,40.82769230769231,40.34923076923077,39.87076923076923,39.39230769230769,38.91384615384615,38.43538461538461,37.956923076923076,37.47846153846154,{"y":37,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.27,"date":1680825600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":36.2,"date":1683244800000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.75,"date":1685664000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":41.78,"date":1688688000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":39.74,"date":1691107200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.5,"date":1693526400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":46.39,"date":1696550400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":47.19,"date":1698969600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":51.63,"date":1701388800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.7,"date":1704412800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":49.75,"date":1706832000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.46,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.22,"date":1712275200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$72.00Average Price Target$58.50Lowest Price Target$37.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Needham
$60.00
Buy
42.05%
Upside
Reiterated
02/21/24
Ionis Pharmaceuticals: A Strong Buy on Robust Revenue Prospects and Clinical Milestones
BMO Capital
$67.00
Buy
58.62%
Upside
Assigned
02/21/24
Ionis Pharmaceuticals: A Strong Buy on ATTR Franchise Prospects and Financial Fortitude
Leerink Partners
$48.00
Hold
13.64%
Upside
Assigned
02/21/24
Analysts' Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (NASDAQ: EXAS), United Therapeutics (NASDAQ: UTHR) and Ionis Pharmaceuticals (NASDAQ: IONS)
RBC Capital
$70.00
Buy
65.72%
Upside
Reiterated
02/21/24
RBC Capital Remains a Buy on Ionis Pharmaceuticals (IONS)
Bank of America Securities
$62.00
Buy
46.78%
Upside
Reiterated
02/15/24
Analysts' Top Healthcare Picks: Ionis Pharmaceuticals (IONS), Glaukos (GKOS)

Best Analysts Covering Ionis Pharmaceuticals

Which Analyst Should I Follow If I Want to Buy IONS and Sell After:
1 Month
Yanan ZhuWells Fargo
Success Rate
8/11 ratings generated profit
73%
Average Return
+2.19%
reiterated a buy rating 4 days ago
Copying Yanan Zhu's trades and holding each position for 1 Month would result in 72.73% of your transactions generating a profit, with an average return of +2.19% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
3 Months
Kostas BiliourisBMO Capital
Success Rate
8/11 ratings generated profit
73%
Average Return
+6.69%
assigned a buy rating 2 months ago
Copying Kostas Biliouris's trades and holding each position for 3 Months would result in 72.73% of your transactions generating a profit, with an average return of +6.69% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
1 Year
Gary NachmanRaymond James
Success Rate
11/15 ratings generated profit
73%
Average Return
+16.73%
initiated a buy rating 7 months ago
Copying Gary Nachman's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +16.73% per trade.
2 Years
Gary NachmanRaymond James
Success Rate
12/15 ratings generated profit
80%
Average Return
+24.44%
initiated a buy rating 7 months ago
Copying Gary Nachman's trades and holding each position for 2 Years would result in 80.00% of your transactions generating a profit, with an average return of +24.44% per trade.
dummydummy
Success Rate
0/0 ratings generated profit
0%
Average Return
0.00%
a rating ―
Copying dummy's trades and holding each position for XXXX would result in 0.10% of your transactions generating a profit, with an average return of 0.00% per trade.
Premium Content
Find out which analyst has the highest Average Return & Success Rate
Go Premium
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

IONS Analyst Recommendation Trends

Rating
Nov 23
Dec 23
Jan 24
Feb 24
Mar 24
Strong Buy
7
6
5
10
13
Buy
15
17
20
21
16
Hold
7
9
9
10
6
Sell
4
5
4
2
1
Strong Sell
0
0
0
0
0
total
33
37
38
43
36
In the current month, IONS has received 29 Buy Ratings, 6 Hold Ratings, and 1 Sell Ratings. IONS average Analyst price target in the past 3 months is $58.50.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
xxxxxxxxxxxxxxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

IONS Financial Forecast

IONS Earnings Forecast

Next quarter’s earnings estimate for IONS is -$1.01 with a range of -$1.40 to -$0.62. The previous quarter’s EPS was -$0.06. IONS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.40% of the time in the same period. In the last calendar year IONS has Underperformed its overall industry.
Next quarter’s earnings estimate for IONS is -$1.01 with a range of -$1.40 to -$0.62. The previous quarter’s EPS was -$0.06. IONS beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 57.40% of the time in the same period. In the last calendar year IONS has Underperformed its overall industry.

IONS Sales Forecast

Next quarter’s sales forecast for IONS is $144.89M with a range of $114.50M to $212.70M. The previous quarter’s sales results were $325.00M. IONS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.30% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.
Next quarter’s sales forecast for IONS is $144.89M with a range of $114.50M to $212.70M. The previous quarter’s sales results were $325.00M. IONS beat its sales estimates 100.00% of the time in past 12 months, while its overall industry beat sales estimates 47.30% of the time in the same period. In the last calendar year IONS has Outperformed its overall industry.

IONS Stock Forecast FAQ

What is IONS’s average 12-month price target, according to analysts?
Based on analyst ratings, Ionis Pharmaceuticals’s 12-month average price target is $58.50.
    What is IONS’s upside potential, based on the analysts’ average price target?
    Ionis Pharmaceuticals has 38.49% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is IONS a Buy, Sell or Hold?
          Ionis Pharmaceuticals has a conensus rating of Moderate Buy which is based on 10 buy ratings, 5 hold ratings and 1 sell ratings.
            What is Ionis Pharmaceuticals’s price target?
            The average price target for Ionis Pharmaceuticals is $58.50. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $72.00 ,the lowest forecast is $37.00. The average price target represents 38.49% Increase from the current price of $42.24.
              What do analysts say about Ionis Pharmaceuticals?
              Ionis Pharmaceuticals’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of IONS?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis